Lung cancer for adults (QS17)
Fast, easy summary view of NICE guidance on 'lung cancer'
Specific, concise statements that act as markers of high-quality, cost-effective patient care
This NICE quality standard defines clinical best practice within this topic area. It provides specific, concise quality statements, measures and audience descriptors to provide the public, health and social care professionals, commissioners and service providers with definitions of high-quality care.
This quality standard covers the diagnosis and management of lung cancer in adults (18 years and over), and the supportive care provided to people with lung cancer.
- NICE clinical guideline: CG121 Lung cancer
- NICE technology appraisal: TA192 Lung cancer (non-small-cell, first line) - gefitinib
- NICE technology appraisal: TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance)
- NICE technology appraisal: TA184 Lung cancer (small-cell) - topotecan
- NICE technology appraisal: TA181 Lung cancer (non-small-cell, first line treatment) - pemetrexed
- NICE clinical guideline: CG27 Referral for suspected cancer
- NICE cancer service guidance: CSGSP Supportive and palliative care
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lung cancer
This page was last updated: 15 April 2013
Quality standard formats
Information for the public
Implementation tools and resources
The summary of the statements in the quality standard written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Full quality standard
The published full quality standard for health and social care professionals, public health practitioners, commissioners, service providers and patients, carers and the public, with quality measures, outcomes definitions and data sources.
Many organisations share NICE's commitment to improve quality by making it clear what quality care is for patients and the public, health and social care professionals, commissioners and service providers.
So that these standards reach the widest possible audience, some of these organisations have endorsed the lung cancer quality standard.
These organisations are: